DeutschNewstral
Article
Fft.com on 2021-06-17 01:01
Biogen’s Japanese partner calls for global action on Alzheimer’s
Related news
FDA approves Biogen’s controversial Alzheimer’s drugNew York Post- FBiogen’s Alzheimer’s drug shows early promiseft.com
Report
Biogen’s Alzheimer’s drug shows early promiseReuters- BBiogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Saysbarrons.com
Analysts see new hope for approval of Biogen’s Alzheimer’s drugbizjournals.com- BAnother Setback for Biogen’s Controversial Alzheimer’s Drug1 min readbarrons.com
- Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in JuneNew York Post
- BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min readbarrons.com
Biogen’s $56 000 Alzheimer’s drug evades Biden’s cost curbspressherald.com- Biogen’s Alzheimer’s drug isn't FDA-approved yet, but it may already have a namebizjournals.com
- BBiogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.barrons.com
- MBiogen’s FDA-approved Alzheimer’s drug, first new remedy in almost twenty yearsmvtelegraph.com
- BBiogen’s Alzheimer’s Drug Inches Closer to Approval. That Doesn’t Make the Stock a Buy.barrons.com
- MBiogen’s controversial Alzheimer’s drug generates $2 million gross sales in first few weeks after approvalmvtelegraph.com
- BThe FDA Delayed Its Decision on Biogen’s Alzheimer’s Drug. The Stock Is Up 10%.barrons.com
- FBiogen’s $56,000-a-year Alzheimer’s drug reignites US debate over costsft.com